EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Asia stocks sink; Japan, S.Korea lead losses as Iran crisis worsens Goldman raises Brent forecasts again, sees higher oil prices for longer Markets steady as Iran, U.S. trade barbs amid Trump’s ultimatum Spike in oil prices seen as ’a clear risk for consumer equities’ 🧠 Upgrade to AI Insights (South Africa Philippines Nigeria) 🧠 Upgrade to AI Insights EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug By Stock Markets Published 03/22/2026, 10:57 PM Updated 03/22/2026, 11:01 PM EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug 0 EYPT -4.06% OCUL -1.09% March 20 - EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug. The complaint was filed in Middlesex County Superior Court for the Commonwealth of Massachusetts. The two companies are rivals in the race to develop longer-lasting treatments for serious retinal diseases, including wet age-related macular degeneration, or wet AMD, a leading cause of vision loss in older adults. EyePoint said Ocular Therapeutix made statements that misrepresented the company and the clinical results of the drug, Duravyu. The company is accusing Ocular Therapeutix of defamation, commercial disparagement, and violations of Massachusetts consumer protection law. It also accused Ocular Therapeutix of interfering with its business relationships. EyePoint is asking the court to order Ocular Therapeutix to stop making the statements, issue a public retraction, and pay monetary damages and legal fees. "We’re confident in our statements and look forward to responding in the course of the legal process," an Ocular spokesperson said. Duravyu is currently being evaluated in late-stage studies for wet age-related macular degeneration and diabetic macular edema, with data for wet AMD expected beginning in mid-2026. Ocular’s leading ...